MERCK KGAA ADR EACH REPR 0.33333 SHS (MKGAY)

22.43
0.24 1.06
OTC
Prev Close 22.67
Open 22.33
Day Low/High 22.25 / 22.43
52 Wk Low/High 19.52 / 27.00
Volume 7.76K
Exchange OTC
Shares Outstanding 387.73B
Market Cap 15.14B
Div & Yield N.A. (N.A)
Will Merck (MKGAY) Stock be Helped by EC Approval of $17 Billion Sigma-Aldrich Deal?

Will Merck (MKGAY) Stock be Helped by EC Approval of $17 Billion Sigma-Aldrich Deal?

Merck (MKGAY) shares are falling but could rebound after European officials approved its $17 billion acquisition of Sigma-Aldrich.

November 17 Premarket Briefing: 10 Things You Should Know

November 17 Premarket Briefing: 10 Things You Should Know

U.S. stock futures fall as data shows Japan slips back into a recession; Actavis nears a deal to acquire Allergan, reports say; Halliburton and Baker Hughes reach merger deal.

European Stocks Follow Asia Lower as Japan Slips Into Recession

European Stocks Follow Asia Lower as Japan Slips Into Recession

European stocks backpedal on Monday, following Asia lower as Japan's economy unexpectedly fell into a recession.

European Stocks Rise, Merck KGaA and Alstom Lead the Advance

European Stocks Rise, Merck KGaA and Alstom Lead the Advance

European stocks rise Thursday, as positive news from companies including Merck KGaA and Alstom led benchmark indices back into positive territory.

European Stocks Trade Mixed as Confidence in Germany Drops

European Stocks Trade Mixed as Confidence in Germany Drops

European stock markets are mixed as a drop in German business confidence stokes new concerns about the pace of economic recovery in Europe.

Germany's Merck to Acquire St. Louis Chemical Firm Sigma Aldrich

Germany's Merck to Acquire St. Louis Chemical Firm Sigma Aldrich

German drug company Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich for $17 billion.

Merck Wins Chinese Approval for AZ Electronics Takeover

Merck Wins Chinese Approval for AZ Electronics Takeover

China's Ministry of Commerce imposes conditions on the $3.1 billion deal.

FLEX: Erbitux Boosts Survival Five Weeks

The much-anticipated lung cancer study shows ImClone's drug increases survival in lung cancer patients, but the results just meet statistical significance.